SUMMARY
Introduction
Cancers presumed to arise from different cell lineages display characteristic genotypes, but cells of origin are generally uncertain and the relationships between lineage-specific attributes and genotypic differences of tumors are not understood(Cancer Genome Atlas Research et al., 2013; Garraway and Lander, 2013) . One of the main obstacles to greater knowledge about these relationships is the need for tractable systems that allow molecular changes observed in mature cancer cells to be evaluated for their contribution to hallmarks of neoplasia as they occur during the development o f specific cell lineages.
Small cell lung cancer (SCLC)---,the most aggressive type of lung cancer, characterized by a poor prognosis, the rapid development of resistance to treatment, and nearly universal loss of function of tumor suppressor genes TP53 and RB---is a relatively common human cancer in need of improved model systems (Gazdar et al., 2017; George et al., 2015; Peifer et al., 2012; Pietanza et al., 2015; Semenova et al., 2015) . Studies of mouse models of SCLC indicate that the target cells for malignant transformation are likely to be pulmonary neuroendocrine cells (PNECs) (Linnoila, 2006; Song et al., 2012; Sutherland et al., 2011) , consistent with the morphology of the cancer cells and expression of neuroendocrine markers. Despite these recent advances, fundamental features of SCLC, especially its initiation, progression, and eventual resistance to therapy, are not understood in relation to its observed genotypes.
To study these problems, we have sought ways to assess functional changes that occur after specific genes are altered in human pulmonary cells at defined stages of tissue development. Recent advances in the induction, cultivation, and directed differentiation of human embryonic stem cells (hESCs) provide opportunities to study carcinogenesis in many human cell types derived from a variety of lineages (Funato et al., 2014) , including cancers such as SCLC, in which rapid onset and progression limit the availability of clinical samples, especially from early stage disease (Pietanza et al., 2015) . In this report, we demonstrate that lung progenitor cells derived from hESCs can be induced to form PNECs by inhibition of NOTCH signaling, that the proportion of PNECs can be specifically increased by inhibition of expression of the RB tumor suppressor gene, and that subsequent interference with the P53 tumor suppressor gene allows xenografted cells to form early stage tumors resembling SCLC.
Results

Generation of PNECs from cultured hESCs.
Methods have recently been described for generating most, but not all, of the cell types observed in adult lung tissues by using growth factors and chemicals to alter signaling pathways sequentially in cells derived from hESCs over several weeks (Fig. 1a) . Using a protocol developed by Huang et al (Huang et al., 2015; Huang et al., 2014) , we have confirmed that, by day 3, about 90% of hESCs (the RUES2 and ES02 lines) differentiate into definitive endoderm Studies of mouse development have suggested that inhibition of signaling via NOTCH receptors might influence cells to adopt a neuroendocrine fate (Ito et al., 2000; Linnoila, 2006; Morimoto et al., 2012; Shan et al., 2007) . In addition, inactivation of NOTCH genes is found in about 25% of SCLCs (George et al., 2015) . Based on these reports, we exposed LPs between 
DAPT induces PNECs by blocking cleavage of NOTCH
We took several approaches to confirm the mechanism by which DAPT induced PNECs.
First, we measured the abundance of NICD in extracts from cells treated with DAPT and observed the expected loss of the γ -secretase cleavage product (Fig. 1d) . To confirm the reduction in NOTCH-mediated signaling, we measured the readout from two NOTCH target genes (Iso et al., 2003) , HES1 and HEY1, and found a marked decrease in levels of transcripts from HEY1 and a slight but significant decrease of RNA from HES1 ( Supplementary Fig. 4a ).
We also tested another known inhibitor of γ -secretase, dibenzazepine (DBZ) (Milano et al., 2004) , and produced percentages of PNECs at day 55 similar to those observed with DAPT ( Fig.   1e ). Finally, we reversed the effects of DAPT by providing NICD, the normal product of γ -secretase-mediated cleavage of NOTCH: expression of a tetracycline-inducible transgene encoding NICD from days 25 to 55 in differentiated RUES2 cells decreased the appearance of CGRP+ cells in cultures concurrently exposed to DAPT ( Fig. 1 f, g )
Single cell transcriptional profiling of induced PNECs.
To further characterize the presumptive PNECs generated by inhibition of NOTCH signaling, we used high-throughput single-cell RNA sequencing (scRNA-seq) applied to DAPTtreated and untreated cells at day 55 ( Fig. 1h -k, Supplementary Fig. 2 b, c, Supplementary Fig. 4 b; see Methods). Clustering of the single-cell profiles revealed one cluster enriched with cells expressing genes that encode CGRP or ASCL1, thus identifying the presumed PNEC cells. In total, the presumed PNEC cells constituted 7.72% of the 9,824 high quality cells (pooled from two biological replicates). Analysis of differential gene expression in the various clusters revealed that cells in cluster 4 exhibit relatively high numbers of transcripts from a set of genes, including CGRP, ASCL1, GRP, SYP, and UCHL1, that encode canonical PNEC markers (Linnoila, 2006; Song et al., 2012) and other genes characteristically expressed in neuroendocrine cells (Fig. 1h, i ). In comparison, we detected CGRP or ASCL1 RNA in only 1.3% percent of cells, and rarely together, from control cultures not treated with DAPT ( Supplementary Fig. 2c.) . Investigation of the other clusters indicates that they express a variety of genes encoding markers specific for several types of lung cells, as also previously noted by Treutlein et al (Treutlein et al., 2014) (Supplementary Fig. 4b ). Some of these marker genes are co-expressed in individual cells, and some are expressed in distinct populations; however, we have not pursued these observations further---for example, to propose differentiation pathways for lung development.
Reduced expression of RB enlarges the proportion of PNECs
Since a central objective of this work is to assess the influence of known lung cancer genes on the behavior of cells in the lung lineage, we next examined the consequences of expressing or simulating known oncogenic mutations in hESC cultures undergoing differentiation, with or without inhibition of NOTCH signaling (Figs 2 and 3). To that end, we equipped the RUES2 hESC line with Dox-inducible transgenes encoding small hairpin RNAs (shRNAs) that inhibit production of RNA from either of the two tumor suppressor genes most commonly inactivated by mutations in SCLC, the RB or TP53 genes ( Supplementary Fig. 5a , b, and Fig. 3 a) . We also introduced into parallel cultures inducible transgenes encoding oncogenes commonly encountered in lung adenocarcinomas, mutant EGFR or mutant KRAS (Cancer Genome Atlas Research, 2014) (Fig. 3 b) .
Induction of RB-specific shRNA in RUES2 cells differentiating to form LCs between days 25 and 50 markedly reduced the amount of RB protein ( Supplementary Fig. 5a ) but not the amounts of the closely related proteins p107 and p130 ( Supplementary Fig. 5b ). Reduced expression of the RB gene was associated with a significantly increased number of CGRP+ NKX2.1+ cells (putative PNECs) from 7.5 ± 2.0% to 37.8 ± 8.2% (Fig. 2a-d) , as measured by FACS, but only when cells were also exposed to DAPT to inhibit processing of NOTCH (Fig.2d) . Similarly, the proportions of cells expressing the PNEC transcription factor ASCL1 and the associated markers NCAM1 and CHGA were also significantly increased (Fig. 2e ).
In contrast, induction of TP53-specific shRNA during the same interval had no effect on the number of CGRP+ cells, with or without DAPT and with or without induction of RB-shRNA ( Fig. 3c-e) . Similarly, induction of mutant forms of EGFR and KRAS proteins between days 25 and 55 ( Fig. 3b) failed to increase the number of CGRP+ cells grown in the absence or presence of DAPT (Fig. 3f, g ). These findings indicate that loss of TP53 or production of mutant EGFR or KRAS proteins do not induce or affect the abundance of PNECs.
The effects of reducing RB levels on PNEC transcriptomes
To examine the transcriptional phenotypes of cultures of differentiated (day 55) RUES2 cells in which both NOTCH and RB signaling were inhibited, we turned again to scRNA-seq.
Similar clustering and differential expression analyses indicate the presence of multiple cell populations in our cultures, including an expanded PNEC-like cell compartment (11.7%), expressing markers similar to those observed in PNEC-like cells at day 55 with normal levels of RB protein ( Supplementary Fig. 6e ). (We attribute the relatively modest increase in PNEC-like cells as judged by scRNA-seq, compared to the increase measured by FACS, to differences in the sensitivity of detection methods that measure RNA levels as opposed to cell surface proteins.) In addition, cells in other clusters contained RNA derived from a variety of genes encoding markers specific for several types of lung cells, as also observed using scRNA-seq to examine cultures treated only with DAPT ( Supplementary Fig. 7a ).
When investigating the heterogeneity within the DAPT-induced PNEC cell cluster, we detected three sub-populations (Supplementary Fig.8a ) with substantially different expression profiles ( Supplementary Fig.8c ). A similar analysis of PNECs from DAPT-treated cultures in which RB levels were reduced also revealed three subpopulations, but with transcriptional profiles different from those in cultures in which RB expression was not altered ( Supplementary   Fig.8a ,c). Some of these differentially expressed genes, including HES1, SST, SCG3, STMN2, ELAVL3, IGFBP4, as well as NEUROD1, have previously been reported to be responsible for the heterogeneity of pulmonary neuroendocrine tumors and implicated in the initiation and progression of human SCLC (Borromeo et al., 2016; Lim et al., 2017) .
To further characterize the effects of the reduction of RB protein on the transcriptional profile of the PNEC cells, we performed a differential expression analysis that compared PNECs appearing after DAPT with PNECs appearing after DAPT combined with reduced expression of RB ( Supplementary Fig.8a ). Subsequent gene function enrichment analysis (Chen et al., 2009) indicated that the most differentially expressed genes following reduction of RB gene expression are involved in regulation of nerve development, apoptosis, TP53 signal transduction, and other processes ( Supplementary Fig.8b and Supplementary file 2). Fig.7 b) . This analysis confirmed that PNEC expression profiles more closely resemble SCLC profiles than do the profiles from non-PNECs. In addition, the similarity to SCLC profiles is greater (P < 2.2e-16
Transcriptomes of PNECs with reduced RB levels resemble transcriptomes from early SCLC.
by two sided Kolmogorov-Smirnov test) in PNECs in which RB levels were reduced than in
PNECs in which RB levels were not perturbed.
Reduction of both P53 and RB in DAPT-induced PNECs allows xenografts to form tumors
To assess the ability of cells in differentiated RUES2 cultures to form tumors, we 
The effects on PNEC transcriptomes of reduced expression of both RB and P53.
Since induction of TP53-specific shRNA, as well as RB-specific shRNA, was required to produce tumor-forming cells in DAPT-treated cells derived from RUES2 cells, we used scRNAseq to seek evidence that might associate the tumorigenic phenotype with changes in PNEC transcriptomes. As indicated earlier (Fig 3c-e Fig. 6e ). In the analysis of cells in which P53 levels were reduced, however, we identified two clear clusters, one differing from the other because its cells show increased expression of genes associated with active cell cycling ( Supplementary Fig. 10e ). This is consistent with the idea that the two clusters are actually one population of PNECs with different proliferation rates, suggesting that reduction of P53 levels, coupled with low levels of RB protein, enables a subset of PNECs to enter a proliferative mode---a phenomenon we did not observe in cells with normal levels of P53, regardless of RB status. We also found that this subset of presumptively proliferating PNECs highly expresses genes associated with inhibition of apoptosis, as well as cell cycle genes, including BIRC5, TOP2A, MKI67, CDK1, CDKN3, CDC20. This indicates that the main effects of reducing P53 levels in PNECs are likely to be proliferative and anti-apoptotic ( Supplementary Fig. 10 e). These effects might account for the appearance of tumor-forming potential in xenografted mice.
The reduction of P53 protein in these cultures also significantly increased the expression of RNA encoding the neuroendocrine transcription factor, NEUROD1,which has been associated with advanced stages of SCLC (Borromeo et al., 2016; Osborne et al., 2013a found that the transcriptomes of PNECs in which levels of both RB and P53 proteins were reduced include enhanced expression of genes associated with cell proliferation and inhibition of apoptosis. These changes may explain the acquisition of tumor forming potential when both tumor suppressor genes have been inhibited, as commonly occurs in human SCLC. They also indicate that it may be possible to assign specific hallmarks of the cancer phenotype to each of the two most common genotypic changes observed in SCLCs---inactivating mutations of the RB and TP53 genes. Additional studies will be required to establish this idea more firmly.
Since the SCLC-like tumors grown subcutaneously in immunodeficient mice appear to have low tumor potency (slow-growing and non-invasive), it is likely that this system will enable studies of tumor progression. In addition, it should be possible to examine cells at different stages of tumor development for susceptibility and resistance to therapeutic strategies, in a manner similar to that used in an earlier study, in which a rare form of glioma was derived from hESCs by genetic manipulation of neural precursors (Funato et al., 2014) .
We recognize that tumorigenesis in an intact organism is a complex process that involves interactions between the cells from which cancer arises and the several types of normal cells---1 stromal, epithelial, vascular, and immunological and other blood cells. These other cell types---and the adjacencies and paracrine effects that might influence tumor initiation and progression---are, of course, missing in the hESC-derived culture system we have described here.
Nevertheless, this system has several advantages: it is based on the use of human rather than non-human cells, and it allows the characterization of substantial numbers of cells subjected to synchronized changes in genotype, gene expression, or hormonal effects.
Although we have begun our evaluation of the ability of manipulated lung cells to form tumors from xenografts at an ectopic site (subcutaneous tissue), it may be possible to study the cells at more appropriate locations, including lung tissue, and we are presently exploring that possibility. Other models, based on the use of genetically altered mice, offer an opportunity to study the generation of cancers like SCLC in a setting in which tissue architecture has not been perturbed, and we view the two approaches as complementary. However, we believe that the use of developmentally controlled human cells to probe the relationship between cancer genotypes and stages of lineage development to be an especially promising feature of the work we have described here.
Notably, we have generated early stage SCLC-like growths only after inducing neuroendocrine cell types and reducing expression of tumor suppressor genes implicated in human SCLC. Thus it seems likely that our differentiation protocol yields cell types, like LPs A m e r i c a n . LPs were further differentiated in mixture VI from days 25 to 55 into the major types of lung cells (LCs) found in mature human lung parenchyma and airway epithelium (Treutlein, et.,al. 2014; Warburton, et.,al. 1998) . Addition of DAPT to mixture VI induced formation of pulmonary neuroendocrine cells (PNECs; red dot), as described in the text. b. 
